medroxyprogesterone acetate has been researched along with HIV in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayele, H; Baeten, JM; Bosinger, SE; Brown, BP; Bunjun, R; Burgener, A; Dabee, S; Gamieldien, H; Harryparsad, R; Heffron, R; Heller, KB; Jaspan, H; Jaumdally, SZ; Nair, G; Noël-Romas, L; Onono, M; Palanee-Phillips, T; Passmore, JS; Ramla, TF; Scoville, CW | 1 |
| Badal-Faesen, S; Cohn, SE; Coughlin, K; Cramer, Y; Dooley, K; Firnhaber, C; Godfrey, C; Kendall, MA; Mawlana, S; Mcilleron, H; Mngqibisa, R; Omoz-Oarhe, A; Roa, J; Robinson, J; Rosenkranz, SL; Samaneka, W; Schnabel, D; Wu, XS | 1 |
| Sathyamala, C | 1 |
| Åhlberg, A; Bradley, F; Broliden, K; Edfeldt, G; Fowke, KR; Khalilzadeh-Binicy, B; Kimani, J; Lajoie, J; Mack, M; Omollo, K; Oyugi, J; Röhl, M; Tjernlund, A; Wählby, C | 1 |
| Achilles, SL; Hapgood, JP; Hel, Z; Polis, CB | 1 |
| Chinula, L; Ellington, S; Haddad, LB; Hosseinipour, MC; Hurst, S; Kourtis, AP; Mataya, R; Msika, A; Nelson, JAE; Tang, JH; Tegha, G; Wiener, J | 1 |
| Baiamonte, L; Drobnis, EZ; Hope, TJ; Huang, L; Li, L; Mills, M; Quayle, AJ; Schust, DJ; Stark, M; Tu, J; Wang, W; Zhou, J | 1 |
| Birse, KD; Bosire, R; Broliden, K; Burgener, AD; Farquhar, C; Guthrie, BL; Kiarie, J; Nilsson, P; Romas, LM | 1 |
| Genescà, M; McChesney, MB; Miller, CJ | 1 |
| Brown, JM; Celentano, DD; Chipato, T; Cornelisse, P; Luoto, J; Mmiro, F; Morrison, CS; Mugerwa, R; Padian, N; Richardson, BA; Rugpao, S; Salata, RA | 1 |
2 trial(s) available for medroxyprogesterone acetate and HIV
| Article | Year |
|---|---|
Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
Topics: Contraceptive Agents, Female; Copper; Disease Susceptibility; Female; HIV; HIV Infections; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Proteomics; South Africa; Vagina | 2022 |
Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
Topics: Adult; Anti-Retroviral Agents; Contraceptive Agents, Female; Female; HIV; HIV Infections; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Vaginal Smears; Virus Shedding | 2018 |
8 other study(ies) available for medroxyprogesterone acetate and HIV
| Article | Year |
|---|---|
Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency.
Topics: Adult; Africa; Contraceptive Agents, Female; Delayed-Action Preparations; Female; HIV; HIV Infections; Humans; Medroxyprogesterone Acetate; Pregnancy; Reference Standards; Tuberculosis | 2020 |
Depot contraception and HIV: an exercise in obfuscation.
Topics: Contraception; Contraceptive Agents, Female; Female; HIV; Humans; Incidence; Intrauterine Devices, Copper; Levonorgestrel; Medroxyprogesterone Acetate | 2019 |
Regular Use of Depot Medroxyprogesterone Acetate Causes Thinning of the Superficial Lining and Apical Distribution of Human Immunodeficiency Virus Target Cells in the Human Ectocervix.
Topics: Cervix Uteri; Contraceptive Agents, Female; Female; HIV; HIV Infections; Humans; Medroxyprogesterone Acetate | 2022 |
Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?
Topics: Adolescent; Adult; Africa South of the Sahara; Contraception; Contraceptive Agents, Female; Delayed-Action Preparations; Female; HIV; HIV Infections; Humans; Injections, Subcutaneous; Medroxyprogesterone Acetate; Risk Factors; Young Adult | 2018 |
Effects of three long-acting reversible contraceptive methods on HIV target cells in the human uterine cervix and peripheral blood.
Topics: Adult; Cervix Uteri; Contraception; Contraceptive Agents, Female; Desogestrel; Female; HIV; HIV Infections; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Receptors, CCR5; Receptors, CXCR4; T-Lymphocytes; Young Adult | 2019 |
Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
Topics: Adult; Carrier Proteins; Cell Adhesion Molecules; Contraceptive Agents, Female; Cross-Sectional Studies; Desiccation; Female; Gardnerella vaginalis; Hemoglobins; HIV; HIV Infections; Humans; Interleukin-1; Kenya; Medroxyprogesterone Acetate; Microbiota; Molecular Motor Proteins; Mucous Membrane; Myosin Heavy Chains; Phagocytosis; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Risk Factors; Trefoil Factor-3; Tumor Suppressor Proteins; Vagina; Young Adult | 2017 |
Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus.
Topics: Animals; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Contraceptive Agents, Female; Female; Flow Cytometry; HIV; Leukocytes, Mononuclear; Macaca; Medroxyprogesterone Acetate; RNA, Viral; Simian Immunodeficiency Virus; Transforming Growth Factor alpha; Transforming Growth Factor beta; Vaccines, Attenuated | 2010 |
Hormonal contraception and the risk of HIV acquisition.
Topics: Adult; Confidence Intervals; Contraception Behavior; Contraceptives, Oral, Hormonal; Delayed-Action Preparations; Disease Transmission, Infectious; Female; Herpes Simplex; Herpesvirus 2, Human; HIV; HIV Infections; Humans; Male; Medroxyprogesterone Acetate; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk; Thailand; Uganda; Zimbabwe | 2007 |